Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
Trial details
- Registry ID
- NCT06880770
- Drugs studied
- Plozasiran
TrialRedline tracks 22 clinical trials sponsored by Arrowhead Pharmaceuticals: 8 Phase 3, 14 Phase 2.
Company identity has not yet been verified
Names as written in the registry records.
NCT05413135 · Arrowhead Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Time frame: Through 24 months. After: Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Description: An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAEs were defined as AEs that started on or after the first dose date of study drug. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. Time frame: Baseline through Month 24.
NCT06347016 · Arrowhead Pharmaceuticals
Before: Active not recruiting. After: Completed.
NCT06347003 · Arrowhead Pharmaceuticals
Before: Active not recruiting. After: Completed.
NCT07473843 · Arrowhead Pharmaceuticals
Before: Not yet recruiting. After: Recruiting.
NCT06822790 · Arrowhead Pharmaceuticals
Before: Estimated. After: Actual.
Before: 869 participants (planned). After: 710 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT07473843 · Arrowhead Pharmaceuticals
Before: 12 participants (planned). After: 10 participants (planned).
NCT06347133 · Arrowhead Pharmaceuticals
Before: Active not recruiting. After: Completed.
NCT07037771 · Arrowhead Pharmaceuticals
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 70 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT06347016 · Arrowhead Pharmaceuticals
Before: Estimated. After: Actual.
Before: Jun 2026. After: 17 Jun 2026.
NCT06347003 · Arrowhead Pharmaceuticals
Before: Estimated. After: Actual.
Before: Jun 2026. After: 12 Jun 2026.
NCT06347133 · Arrowhead Pharmaceuticals
Before: Estimated. After: Actual.
Before: May 2026. After: 1 Jun 2026.
NCT05089084 · Arrowhead Pharmaceuticals
Before: Active not recruiting. After: Completed.
NCT05217667 · Arrowhead Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent Change from Baseline in Fasting Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) and LDL-C by Preparative Ultracentrifugation (LDL-C [PUC]) up to Week 24. After: Measure: Percent Change From Baseline in Fasting LDL-C at Week 24.
Before: Active not recruiting. After: Terminated.
NCT05413135 · Arrowhead Pharmaceuticals
Before: 18 Sep 2025. After: 22 Sep 2025.
NCT07241546 · Arrowhead Pharmaceuticals
Before: Not yet recruiting. After: Recruiting.
NCT04720534 · Arrowhead Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24. After: Measure: Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG).
NCT04998201 · Arrowhead Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24. After: Measure: Percent Change From Baseline at Week 24 in Fasting TG.
NCT05089084 · Arrowhead Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Month 10. After: Measure: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG).
NCT05413135 · Arrowhead Pharmaceuticals
Before: Estimated. After: Actual.
Before: Sep 2025. After: 18 Sep 2025.
Before: Active not recruiting. After: Completed.